Nanoscope Secures Major Global Wins for MCO-010 with EMA and FDA Designations
The race to restore sight for patients living with retinal degeneration just gained serious momentum. Nanoscope Therapeutics (Texas, United States)…
FDA Clears Ocugen’s Phase II/III Trial for Stargardt Disease Gene Therapy
Ocugen’s OCU410ST gene therapy gets another green light. Next stop: a Phase II/III trial. The U.S. Food and Drug Administration…
latest posts
